New Non-Opioid Pain Drugs Arrive, but Insurance Hurdles Remain

The opioid crackdown has strained the patient-clinician relationship, prompting a search for safer analgesics. In January 2025 the FDA approved Journavx, the first non-opioid drug that blocks peripheral sodium channels, and it has already filled roughly 900,000 prescriptions in its first half-year. A separate study of LTG-001 showed it cut pain scores and opioid rescue medication after abdominal surgery, though higher doses were linked to fever and presyncope.

Medicare’s recent policy adds non-opioid drugs like Journavx to its temporary payment list, yet physicians report prior-authorization paperwork consumes an average of 13 weekly hours, delays treatment for 95% of respondents, and drives patients to abandon therapy. Survey data also link authorization delays to adverse events, increased healthcare utilization, and clinician burnout. The article argues that without simplifying insurance processes, the promise of new pain therapies will be undermined.